Susquehanna Fundamental Investments’s Cytokinetics CYTK Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-19,387	Closed	-$779K	–	796
2025 Q1	$779K	Sell	19,387 -112,412	-85%	-$5.17M	0.01%	750
2024 Q4	$6.2M	Buy	+131,799	New	+$6.84M	0.09%	288
2024 Q2	$6.79M	Buy	125,271 +58,195	+87%	+$3.51M	0.16%	176
2024 Q1	$4.7M	Buy	+67,076	New	+$5.19M	0.22%	122
2023 Q1	–	Sell	-23,072	Closed	-$1.06M	–	984
2022 Q4	$1.06M	Buy	23,072 +12,289	+114%	+$529K	0.02%	643
2022 Q3	$522K	Buy	+10,783	New	+$519K	0.01%	1003
2022 Q1	$1.03M	Buy	28,130 +9,440	+51%	+$335K	0.02%	827
2021 Q4	$852K	Buy	18,690 +5,690	+44%	+$220K	0.02%	711
2021 Q3	$465K	Buy	+13,000	New	+$383K	0.01%	1247

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Susquehanna Fundamental Investments's CYTK Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 19,387 shares — an estimated $779K sold.

Susquehanna Fundamental Investments first reported a position in CYTK in Q3 2021 and held it in 9 quarters. The position peaked at $6.79M in Q2 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 19,387 Cytokinetics shares in Q2 2025, an estimated $779K.
Susquehanna Fundamental Investments first reported a position in Cytokinetics in Q3 2021 and held it in 9 quarters.
Susquehanna Fundamental Investments's Cytokinetics position peaked at $6.79M in Q2 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.